First-line immunochemotherapy for extranodal natural killer/T cell lymphoma
Mené sur 34 patients atteints d'un lymphome extra-ganglionnaire à cellules T/NK de stade avancé (âge médian : 39 ans ; durée médiane de suivi : 21 mois), cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse complète, et la toxicité d'un traitement de première ligne combinant sintilimab et chimiothérapie de type P-GEMOX (pégaspargase, gemcitabine et oxaliplatine)
We congratulate Xiao-Peng Tian and colleagues 1 for their Article in The Lancet Haematology, on the achievement of the promising result of their trial investigating first-line immunochemotherapy for advanced-stage extranodal NK/T-cell lymphoma (ENKTL). With the advantage of asparaginase-based regimens and standardised radiotherapy, the outcome of ENKTL has been substantially improved during the past decade, 2 particularly in early-stage disease (5-year overall survival 55–90%). 3 However, the prognosis of patients with advanced-stage disease is still extremely poor with 5-year overall survival of 30–40% presenting the best effectiveness for current cytotoxic regimens. In the SPIRIT study, 1 sintilimab and P-GMOX (pegaspargase, gemcitabine, and oxaliplatin) showed favourable outcomes with manageable toxicities in advanced-stage ENKTL, with a complete response rate of 85% (95% CI 70–94) and 2-year progression-free survival (PFS) of 64% (48–86).